KKR's LGC buys SeraCare from Linden Capital

Following the acquisition, LGC expects to consolidate its position in the clinical quality-control tools market and expand its existing calibration verification materials and testing offerings.

US healthcare-focused private equity firm Linden Capital bought SeraCare in 2012 in a take-private deal that valued the company at around $81m. Under Linden's ownership, SeraCare was able to leverage its product portfolio and successfully launch and commercialise a clinical genomics business unit, according to a statement.

KKR bought British life sciences company LGC in December 2015 from Bridgepoint. According to press reports published at the time, the deal was valued at around £650m. The sale ended a five-year holding period for Bridgepoint, following its acquisition of LGC from LGV Capital for £257m in 2010.

Company
Founded in 1984 as Boston Biomedica and headquartered in Milford, Massachusetts, SeraCare provides quality-control materials for infectious-disease testing used by in-vitro diagnostics specialists, clinical laboratories and pharmaceutical companies.

The business employs 170 staff at two locations based in Milford, Massachusetts, and Gaithersburg, Maryland. Its product segments include bulk plasma, panels for research and development of diagnostic assays, and clinical controls for calibration of diagnostic laboratory instrumentation for both molecular diagnostics and next-generation sequencing.

People
LGC – Euan O'Sullivan (managing director, standards division).
Linden Capital Partners – Brian Miller (managing partner).
SeraCare Life Sciences – Charlie Mamrak (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• UK / Ireland
• Healthcare
• KKR
• United Kingdom
• Buy-and-build
• Build-up
• Trade sale